Cardium Therapeutics (OTCBB:CDTP) announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the Company’s lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF-4) for the potential treatment of myocardial ischemia. [click link for full article]
More: continued here